PedAM
Pediatric Disease Annotations & Medicines
| Disease | pyoderma |
| Phenotype | C0021831|bowel disease |
| Sentences | 10 |
| PubMedID- 23828140 | Conclusions: oral corticosteroid therapy remains the most common treatment for pyoderma gangrenosum associated with inflammatory bowel disease. |
| PubMedID- 20645536 | The authors report a case of rapid response to infliximab in a patient with pyoderma gangrenosum associated with inflammatory bowel disease utilizing a dosing regimen similar to that used for psoriasis. |
| PubMedID- 20466360 | [utility of infliximab in gangrenous pyoderma not associated with inflammatory bowel disease]. |
| PubMedID- 21958000 | Successful treatment with infliximab for refractory pyoderma gangrenosum associated with inflammatory bowel disease. |
| PubMedID- 21352279 | Clinical implications of leukocytapheresis using a centrifugal cell separator for steroid-resistant pyoderma gangrenosum associated with inflammatory bowel disease. |
| PubMedID- 22104047 | pyoderma gangrenosum associated with inflammatory bowel disease. |
| PubMedID- 21625613 | Results: literature review of 10 cases confirmed the association of pyoderma gangrenosum with inflammatory bowel disease, hematological disease, and surgical trauma. |
| PubMedID- 21953808 | Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. |
| PubMedID- 21532836 | Cd2bp1 (pstpip1) and card15 mutations are not associated with pyoderma gangrenosum in patients with inflammatory bowel disease (table 1) [29]. |
| PubMedID- 23927379 | Background and aim: to identify predictive factors related to the development of erythema nodosum and pyoderma gangrenosum, in patients with inflammatory bowel disease (ibd). |
Page: 1